Thiazolidinediones × glycemic control

TrialDiabetes, obesity & metabolism2025

Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial.

Eun-Gyoung Hong et al.PubMed ↗Full text ↗Publisher ↗

  • Lobeglitazone (0.5 mg/day)looks good hereLower long-term blood sugar, no range given.No ranges given.

What the trial testedas reported · 2025

No range given

Reported lower long-term blood sugar, no range given

−1.03percentage points

lobeglitazone (0.5 mg/day) vs placebo

As reported

difference −1.03 %, no interval · the paper's word: HbA1c

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

lobeglitazone (0.5 mg/day)
placebo

Reported lower long-term blood sugar, no range given−1.03

randomised

the abstract, start to end

difference in the adjusted mean change [-1.03%; p < 0.0001].

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
HbA1clobeglitazone (0.5 mg/day) vs placebo
−1.03
ThiazolidinedionesGlycemic control

Thiazolidinediones × glycemic controlhelps?settled

unlikelylikely
0.830.80 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

3 papers cite it

2025
2026
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40726438